Top-News
Donnerstag,
27.10.2016 12:05
von
PR Newswire
| Aufrufe: 31
United Therapeutics Corporation Reports Third Quarter 2016 Financial Results
Eine Tageszeitung (Symbolbild).
pixabay.com
PR Newswire
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2016
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2016 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2016.
"Our financial performance continues its strength this quarter," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Our growth potential is higher than ever, with new programs in our pipeline for pulmonary hypertension associated with emphysema, fibrosis, heart failure and sickle cell disease. In addition we are launching the clinical development of our dinutuximab monoclonal antibody for small cell lung cancer and other high-risk forms of cancer with GD2 expressing cell tumors. Finally, our second generation parenteral drug delivery systems for treprostinil are continuing their march toward anticipated approvals in 2017 for implantable and 2018 for subcutaneous."
Key financial highlights include (dollars in millions, except per share data):
| | | Three Months Ended | | Percentage | | ||||||||||||||
| | | 2016 | | 2015 ARIVA.DE Börsen-GeflüsterWerbung Weiter aufwärts?
 Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME4CZT,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
| | Changes | | ||||||||||||
| | | | | | | | | ||||||||||||
| Revenues | | $ | 408.2 | | $ | 386.2 | | 5.7% | | ||||||||||
| Net income | | $ | 161.8 | | $ | 464.4 | | (65.2)% | | ||||||||||
| Non-GAAP earnings(1) | | $ | 201.5 | | $ | 174.7 | | 15.3% | | ||||||||||
| Net income, per diluted share | | $ | 3.50 | | $ | 9.24 | | (62.1)% | | ||||||||||
| Non-GAAP earnings, per diluted share(1) | | $ | 4.36 | | $ | 3.48 | | 25.3% | | ||||||||||
____________________
| (1) | See definition of non-GAAP earnings, a non-GAAP financial measure, and a reconciliation of net income to non-GAAP earnings below. |
Financial Results for the Three Months Ended September 30, 2016
Revenues
The table below summarizes the components of total revenues (dollars in millions):
| | | Three Months Ended | | Percentage | | ||||
| | | 2016 | | 2015 | | Change | | ||
| Net product sales: | | | | | | | | ||
| Remodulin® | | $ | 152.4 | | $ | 150.1 | | 1.5% | |
| Tyvaso® | | 101.8 | | 121.7 | | (16.4)% | | ||
| Adcirca® | | 96.0 | | 73.8 | | 30.1% | | ||
| Orenitram® | | 40.7 | | 34.4 | | 18.3% | | ||
| Unituxin® | | 17.3 | | 4.7 | | 268.1% | | ||
| Other | | — | | 1.5 | | (100.0)% | | ||
| Total revenues | | $ | 408.2 | | $ | 386.2 | | 5.7% | |
Revenues for the three months ended September 30, 2016 increased by $22.0 million, compared to the same period in 2015. The growth in revenues primarily resulted from the following: (1) a $22.2 million increase in Adcirca net product sales; (2) a $12.6 million increase in Unituxin net product sales; (3) a $6.3 million increase in Orenitram net product sales; and (4) a $2.3 million increase in Remodulin net product sales. These increases were partially offset by a $19.9 million decrease in Tyvaso net product sales.
Expenses
Cost of product sales. The table below summarizes cost of product sales by major categories (dollars in millions):
| | | Three Months Ended | | Percentage | | ||||
| | | 2016 | | 2015 | | Change | | ||
| Category: | | | | | | | | ||
| Cost of product sales | | $ | 20.0 | | $ | 15.0 | | 33.3% | |
| Share-based compensation expense (benefit) Werbung Mehr Nachrichten zur United Therapeutics Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | |||||||||
